Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.
Website7946 Ivanhoe Avenue
La Jolla, CA, 92037
United States
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.
SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.
Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.
Investors talking about ENSC also mention
What share of all stock conversation is about ENSC?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% -0.01 | 0% 0 |
Of the messages about ENSC that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 25% | 27.27% +12.99 | 80.95% +10.73 | 78.47% -7.71 | ||
| Bearish | 75% | 72.73% -12.99 | 19.05% -10.73 | 21.53% +7.71 |
Of the messages about ENSC that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 84.62% | 39.53% | ||
| Technical Analysis | — | 0% | 11.54% | 43.72% | ||
| Controversies | — | 0% | 3.85% | 0.45% | ||
| Earnings | — | 0% | 0% | 0.5% | ||
| Analysts | — | 0% | 0% | 8.13% | ||
| Macro | — | 0% | 0% | 7.67% |
Of the messages about ENSC, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 50% | 78.26% | 65.55% | 44.05% | ||
| Newcomers | 50% | 21.74% | 34.45% | 55.95% |